The SWITCH Study (Sensing With Insulin pump Therapy to Control HbA 1c ): Design and Methods of a Randomized Controlled Crossover Trial on Sensor-Augmented Insulin Pump Efficacy in Type 1 Diabetes Suboptimally Controlled with Pump Therapy
Open Access
- 1 January 2011
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 13 (1) , 49-54
Abstract
Background: Studies investigating the effect of real-time continuous glucose monitoring (CGM) combined with pump therapy on glycemic outcomes in type 1 diabetes are increasing. Pump therapy is well established as a “gold standard” for insulin delivery, offering improvements over multiple daily insulin injections. However, there is still a proportion of subjects using continuous subcutaneous insulin infusion in whom goals for metabolic control are far from achieved or benefits of this type of insulin therapy are transient. The SWITCH (Sensing With Insulin pump Therapy to Control HbA1c [hemoglobin A1c]) study is a multicenter, randomized, controlled, crossover study to evaluate if adding CGM to experienced pump patients with suboptimal metabolic control will provide additional insight enabling clinical and therapeutic benefit. Methods: Subjects meeting the inclusion criteria were randomized to Sensor On or Sensor Off arms for 6 months, after a 1-month run-in period. Following a 4-month washout period, the subjects crossed over to the other study arm for 6 months. The primary end point was the between arm difference in HbA1c levels. Among others, additional end points include time spent in different glycemic ranges, percentage of patients with HbA1c Results: Recruitment occurred between January 2008 and February 2009. A total of 153 patients were randomized. Study completion is anticipated in July 2010. Conclusions: The results will establish if adding CGM to existing, capable, insulin pump users can enable better metabolic control.Keywords
This publication has 13 references indexed in Scilit:
- Incremental Value of Continuous Glucose Monitoring When Starting Pump Therapy in Patients With Poorly Controlled Type 1 DiabetesDiabetes Care, 2009
- Improved Glycemic Control through Continuous Glucose Sensor-Augmented Insulin Pump Therapy: Prospective Results from a Community and Academic Practice Patient RegistryJournal of Diabetes Science and Technology, 2009
- Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trialDiabetologia, 2009
- Continuous Glucose Monitoring and Intensive Treatment of Type 1 DiabetesNew England Journal of Medicine, 2008
- Sensor-Augmented Insulin Pump Therapy: Results of the First Randomized Treat-to-Target StudyDiabetes Technology & Therapeutics, 2008
- Improved Glycemic Control in Poorly Controlled Patients with Type 1 Diabetes Using Real-Time Continuous Glucose MonitoringDiabetes Care, 2006
- Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trialDiabetic Medicine, 2005
- Continuous Subcutaneous Glucose Monitoring Improved Metabolic Control in Pediatric Patients With Type 1 Diabetes: A Controlled Crossover StudyPediatrics, 2003
- A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic ControlDiabetes Care, 2002
- Measures of Psychological Well‐being and Treatment Satisfaction Developed from the Responses of People with Tablet‐treated DiabetesDiabetic Medicine, 1990